On January 20, 2023, ImmuneOnco Biomedical Technology (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that the first domestic SIRPαFc fusion protein drug targeting human CD47 (project number: IMM01) combined with PD-1 monoclonal antibody against relapsed and refractory classical Hodgkin's lymphoma (R/RcHL) completed the first subject's enrollment and administration of the Phase II clinical trial.

The performance of IMM01 in the clinical phase I study of a single drug is encouraging. At a lower dose level, some patients with advanced lymphoma (including relapsed and refractory cHL) have good clinical efficacy and good safety. sex. Based on the molecular design characteristics of IMM01, IMM01 does not bind to human red blood cells in vitro at all, avoiding the "antigen sink effect". The molecule is only about half of the antibody, and has good tissue permeability and bioavailability. At the same time, in the preclinical in vivo drug efficacy test, IMM01 was used in combination with targeted drugs and immunotherapy drugs, showing strong tumor suppressive activity against solid tumors, and has the potential of combination therapy.

Dr. Tian Wenzhi, Founder and Chairman of ImmuneOnco, said,

"I am very pleased to see that the phase II clinical trial of our IMM01 project combined with PD-1 monoclonal antibody for relapsed and refractory classical Hodgkin's lymphoma (R/RcHL) has completed the first patient enrollment and administration. Preclinical studies have shown that The combination of IMM01 and PD-1 monoclonal antibody has a strong synergistic effect. In the patients enrolled in the combination, it showed good safety and tolerability, and it was observed in patients with non-small cell lung cancer resistant to previous PD1 therapy Preliminary positive efficacy response. We have reason to believe that in further clinical studies, IMM01 combined with PD-1 monoclonal antibody will show outstanding clinical efficacy and good safety, which is very hopeful to bring good news to the majority of cancer patients. It is our company's mission to develop first-class new medicines, and we will unswervingly pursue this dream."